| Literature DB >> 14515255 |
Cezmi A Akdis1, Fatimah Kussebi, Bali Pulendran, Mübeccel Akdis, Roger P Lauener, Carsten B Schmidt-Weber, Sven Klunker, Gülbu Isitmangil, Natasha Hansjee, Thomas A Wynn, Stephanie Dillon, Peter Erb, Gerhard Baschang, Kurt Blaser, Sefik S Alkan.
Abstract
In allergy and asthma, the fine balance between the T helper (Th) 1, Th2 and T regulatory cytokine responses appears to be shifted towards Th2. Here, we report that synthetic lipopeptides which contain the typical lipid part of the lipoprotein of gram-negative bacteria stimulate a distinct regulatory cytokine pattern and inhibit several Th2 cell-related phenomena. The most potent analogue of synthetic lipopeptides, lipopeptide CGP 40774 (LP40) was not active in MyD88-deficient mice and stimulated Toll-like receptor (TLR)-2, but not TLR-4. LP40 potentiated the production of IFN-gamma and IL-10, but not IL-4 and IL-5 by human T cells. In addition, triggering of TLR-2 by lipopeptides promoted the in vitro differentiation of naive T cells towards IL-10- and IFN-gamma-producing T cells and suppressed IL-4 production by Th2 cells. Accordingly, LP40 inhibited IgE production induced by allergen, anti-IgD antibody, Nippostrongylus brasiliensis or murine acquired immunodeficiency virus. Furthermore, ovalbumin-induced lung eosinophilic inflammation was abolished and Schistosoma mansoni egg-induced granuloma size and eosinophil counts were suppressed in mice by LP40. These results demonstrate that stimulation of TLR-2 by lipopeptides represents a novel way for possible treatment of allergy and asthma by regulating the disrupted cytokine balance.Entities:
Mesh:
Substances:
Year: 2003 PMID: 14515255 DOI: 10.1002/eji.200323329
Source DB: PubMed Journal: Eur J Immunol ISSN: 0014-2980 Impact factor: 5.532